Description
Description
Survodutide (BI 456906) is an investigational once-weekly dual agonist of the GLP-1 and glucagon receptors, showing significant potential for treating obesity and MASH (metabolic dysfunction-associated steatohepatitis). It demonstrates high efficacy in reducing body weight (up to 18.7% in studies), improving liver fibrosis, and enhancing metabolic health
Composition
- Survodutide: 10 mg
- Appearance: lyophilized powder in a sealed research vial
Research Focus (non-clinical)
- Identity and purity assessment
- Chromatographic method optimization for variant/impurity profiling
- Stability characterization of a lyophilized peptide under laboratory storage conditions
Documentation
- Lot-specific COA available
- Batch and lot traceability
Important Notice
- For research use only
- Not for human consumption
- Not intended to diagnose, treat, cure, or prevent any disease
Quality & Manufacturing
- Lot-specific COA
- Lyophilized for transit stability; batch traceable
- Tamper-evident seal; lot & test date on each vial
- No MOQ for online orders
- Bulk orders for physical locations start at 25-unit minimum
